Phenylketonuria (PKU) is a rare inherited condition that affects how the body processes protein, specifically an amino acid called phenylalanine. Without proper management, this condition can lead to serious health complications, but when identified early and treated consistently, people with PKU can live full and healthy lives.

Epidemiology

Phenylketonuria is a rare genetic condition that affects a small portion of the population worldwide. In the United States, PKU occurs in approximately one in every 15,000 to 25,000 newborns, which means there are currently an estimated 13,500 individuals living with this condition in the country as of 2024^[1][3][11]. The occurrence of PKU varies significantly among different ethnic groups and geographic regions around the world. Some populations have higher rates of the condition, while others have lower rates, depending on genetic factors that influence how common the disease-causing gene variants are in those communities^[3].

One of the most important public health achievements in managing PKU has been the implementation of universal newborn screening programs. All 50 states in the United States and many other countries around the world now require that babies be screened for PKU shortly after birth, typically within the first day or two of life^[1][4]. This early detection system has dramatically changed the outlook for people with PKU. Most cases are now detected promptly, allowing treatment to begin right away before any symptoms develop. As a result, the severe signs and symptoms that were once commonly seen in people with classic PKU are now rarely encountered^[3].

PKU was actually the first condition to be included in newborn screening programs when testing began in the 1960s. Massachusetts piloted newborn screening in 1962, and in 1963, Boston Children’s Hospital opened the world’s first PKU clinic^[4][20]. This historic achievement demonstrated that early detection and treatment could prevent intellectual disability and other serious complications, paving the way for expanded newborn screening programs that now test for dozens of conditions.

Causes

Phenylketonuria is caused by changes, also called pathogenic variants or mutations, in a specific gene known as the PAH gene. This gene provides the body with instructions on how to produce an important enzyme called phenylalanine hydroxylase (PAH). An enzyme is a type of protein that helps speed up chemical reactions in the body. In this case, the PAH enzyme is responsible for converting phenylalanine, an amino acid found in protein-rich foods, into another amino acid called tyrosine^[2][3].

When someone has PKU, the mutations in their PAH gene mean that their body either produces very little of the PAH enzyme, or the enzyme that is produced doesn’t work properly. Without enough functioning PAH enzyme, the body cannot break down phenylalanine effectively. This causes phenylalanine to accumulate to harmful levels in the blood and brain^[1][2]. Phenylalanine is an essential amino acid, which means the body needs it but cannot make it on its own—it must come from food. Under normal circumstances, the body uses what it needs and converts the excess into other useful substances, but people with PKU lack this ability^[5].

There are over 1,000 different mutations that can cause PKU, with varying degrees of severity. The most common mutation replaces one building block of the enzyme (an amino acid called arginine) with another (tryptophan) at a specific position^[5]. Most PKU-causing mutations result from the PAH enzyme being misfolded or unstable, which prevents it from working properly. The severity of PKU depends on how much enzyme activity remains. Classic PKU, the most severe form, occurs when there is very little or no enzyme activity at all, resulting in blood phenylalanine levels greater than 1,200 micromolar. Less severe forms include mild PKU, with levels between 600 and 1,200 micromolar, and mild hyperphenylalaninemia, with levels below 600 micromolar^[5].

Risk Factors

The primary risk factor for developing phenylketonuria is inheriting the condition from both biological parents. PKU follows what is called an autosomal recessive pattern of inheritance. This means that for a baby to be born with PKU, they must receive two copies of the changed PAH gene—one from each parent^[2][9]. Parents who each carry one copy of the changed gene are called carriers. Carriers typically do not have PKU themselves because they still have one working copy of the gene, which is usually sufficient for the enzyme to function adequately.

When both parents are carriers of a PKU gene mutation, there is a 25 percent chance with each pregnancy that their child will inherit both changed genes and have PKU. There is a 50 percent chance the child will inherit one changed gene and become a carrier like the parents, and a 25 percent chance the child will inherit two normal genes. Genetic testing can identify carriers through a blood test, which can be helpful for family planning purposes^[2][7].

A special risk situation involves women with PKU who become pregnant. If a woman with PKU is not following a low-phenylalanine diet during pregnancy, her baby faces significant risks even if the baby doesn’t have PKU. High levels of phenylalanine in the mother’s blood during pregnancy can cross the placenta and affect the developing baby. This is known as maternal PKU syndrome. Babies exposed to high phenylalanine levels before birth may experience intellectual disability, low birth weight, slower growth than other children, heart defects or other heart problems, an abnormally small head size called microcephaly, and behavioral problems^[2][3]. Women with PKU who are not managing their condition also have a higher risk of miscarriage^[2]. However, women with well-managed PKU can have healthy pregnancies and babies^[2].

Symptoms

Newborns with phenylketonuria appear completely healthy at birth. There are no visible signs or symptoms in the first few weeks of life. This is why newborn screening is so crucial—it identifies the condition before any damage occurs. Without treatment, symptoms typically begin to develop slowly over the first three to six months of life^[1][2][9].

The earliest signs that parents may notice are often developmental delays. The baby may not reach milestones at the expected times. By around one year of age, if PKU remains untreated, additional symptoms may become apparent. One distinctive sign is a musty or mouse-like odor that can be detected in the baby’s breath, sweat, and urine. This unusual smell is caused by the buildup of excess phenylalanine in the body^[1][2][3].

Children with untreated PKU often have lighter skin, hair, and eye color compared to other family members. This happens because phenylalanine normally gets converted into tyrosine, which is needed to produce melanin, the pigment that gives color to skin, hair, and eyes. Without enough tyrosine being produced, less melanin is made^[1][3]. Skin problems are also common, particularly eczema, which causes patches of skin to become itchy, dry, and inflamed^[1][2].

Other physical symptoms that may develop in untreated children include nausea and vomiting, reduced growth, a smaller than normal head size, tremors, and seizures, which are episodes of abnormal electrical activity in the brain that can cause convulsions^[1][2][3]. The most serious consequence of untreated PKU is permanent brain damage leading to intellectual disability, which can range from mild to severe. Children may also experience behavioral problems including frequent temper tantrums, self-harm, hyperactivity, and psychiatric disorders such as anxiety^[2][3].

Even in people who were treated as children but stopped treatment later in life, symptoms can develop or return. Adults with untreated or inadequately treated PKU may experience what is often described as “brain fog”—a feeling of decreased mental clarity and slowed processing of information. They may have difficulty with memory, attention, decision-making, problem-solving, and planning. Mood-related issues are also common, including depression, anxiety, and irritability^[2][19][20]. The encouraging news is that many of these symptoms can be at least partly reversed when people return to treatment^[2][20].

Prevention

Because phenylketonuria is an inherited genetic condition, there is no way to prevent someone from being born with it. However, the serious complications of PKU can be prevented through early detection and lifelong treatment. The cornerstone of prevention is newborn screening, which has been tremendously successful. When PKU is identified within the first few days of life and treatment begins immediately, children can avoid the intellectual disability and other severe symptoms that would otherwise occur^[1][3][4].

For people already diagnosed with PKU, preventing complications requires consistent adherence to treatment throughout life. Current recommendations from health authorities, including the National Institutes of Health, emphasize that dietary treatment should continue for life, not just during childhood^[18][21]. People who maintain good control of their phenylalanine levels have better mental and physical health outcomes compared to those who don’t^[22].

For women with PKU who are thinking about becoming pregnant, prevention takes on special importance. To prevent maternal PKU syndrome and protect the developing baby, women need to achieve strict metabolic control before conception and maintain it throughout pregnancy. This means getting blood phenylalanine levels within a safe range before becoming pregnant, which typically requires several months of careful dietary management or medication. Preventing unplanned pregnancies is also crucial, as the most critical period for fetal development occurs in the first weeks of pregnancy, often before a woman knows she is pregnant^[2][18].

Genetic counseling can help families understand their risks. If someone has PKU or a family history of the condition, genetic testing can identify whether other family members are carriers. Screening tests before pregnancy or birth can also be recommended to assess risk^[1][7]. Some couples who are both carriers may choose to use reproductive technologies that can test embryos before pregnancy, though this is a personal decision that families make based on their own values and circumstances.

Pathophysiology

Understanding what happens in the body when someone has PKU helps explain why treatment is so important. Normally, when a person eats protein-containing foods, the protein is broken down during digestion into individual amino acids. One of these amino acids is phenylalanine, which the body needs in small amounts for building proteins and making other important substances. Phenylalanine is considered an essential amino acid because the body cannot manufacture it and must obtain it from food sources such as meat, eggs, dairy products, nuts, and milk^[2][3].

In people without PKU, excess phenylalanine that isn’t needed for protein synthesis is converted into tyrosine by the PAH enzyme, which is primarily found in the liver. This conversion requires a cofactor called tetrahydrobiopterin (BH4), which is a helper molecule that the enzyme needs to function properly^[5][12]. Tyrosine then goes on to be used for making important substances including neurotransmitters (chemical messengers in the brain), thyroid hormones, and melanin.

In people with PKU, the PAH enzyme is either absent or doesn’t work effectively because of genetic mutations. This means phenylalanine cannot be converted to tyrosine efficiently. As a result, phenylalanine accumulates in the blood and reaches the brain, where it crosses the blood-brain barrier, a protective layer that normally controls what substances can enter the brain. High levels of phenylalanine are particularly toxic to nerve cells in the brain^[3][5].

The mechanism by which elevated phenylalanine damages the brain is complex. High phenylalanine levels interfere with the transport of other important amino acids into the brain, disrupting the production of neurotransmitters that are essential for normal brain function and development. This interference affects communication between brain cells and can impair the formation of myelin, the protective coating around nerve fibers that allows signals to travel quickly and efficiently. Over time, especially during the critical period of brain development in early childhood, these disruptions lead to permanent structural and functional changes in the brain^[5].

At the same time, because phenylalanine is not being converted to tyrosine, people with PKU have lower levels of tyrosine than normal. This contributes to some of the symptoms of PKU, particularly the lighter skin and hair color, since tyrosine is needed to produce melanin. The lack of tyrosine may also affect the production of neurotransmitters like dopamine and norepinephrine, which could contribute to attention and mood problems^[2][5].

The degree of enzyme deficiency determines the classification and severity of PKU. In classic PKU, there is less than 1 percent of normal PAH enzyme activity, leading to blood phenylalanine levels that can rise well above the safe range without treatment. In milder forms, some residual enzyme activity remains, allowing the body to process small amounts of phenylalanine, though still not enough for a normal diet^[5]. This variation in enzyme activity explains why some people with PKU can tolerate more dietary protein than others and why treatment must be individualized.